Catalyst Pharmaceuticals, Inc.
About
31.23USD-0.06 -0.19%
Closed • Updated at 01:48 GMT+00:00Market Cap$3.82B
P/E Ratio17.95
Volume2.61M
Beta0.45
RSI71.58
Gross Margin79.62%
Catalyst Pharmaceuticals, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 11 2026
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
May 7 2026
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
May 7 2026
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
Apr 28 2026
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
Mar 6 2026
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
Recent Videos
Catalyst Pharmaceuticals (CPRX) Analysis: Zero-Debt Biotech Faces $4.1B Acquisition
May 18, 2026
CATALYST PHARMACEUTICALS INC 2026 quarterly report
May 16, 2026
CPRX, Catalyst Pharmaceuticals, Inc., 2026-04-27, stock prices dynamics, stock of the day
Apr 28, 2026
Catalyst Pharmaceuticals Stock Analysis | Ultra-Orphan Drug Margins Power Valuation
Mar 06, 2026
Community Chat
Ask AI
Try asking